t(8;16) AML developed subsequent to breast cancer therapy

Author： Sahin Feride Iffet   Yilmaz Zerrin   Karakuş Sema   Boĝa Salih   Akçali Zefer   Demirhan Beyhan  

Publisher： Maney Publishing

ISSN： 1024-5332

Source： Hematology, Vol.11, Iss.3, 2006-06, pp. : 153-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epigenetic therapy in MDS and acute AML: focus on decitabine

By Lübbert M.   Wijermans P.  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 1-2

Springer Publishing Company

Access to resources Recommend Favorite

Second malignancies after breast cancer: The impact of adjuvant therapy (Review)

By    

Molecular and Clinical Oncology, Vol. 2, Iss. 3, 2014-01 ,pp. : 331-336

Spandidos Publications

Access to resources Recommend Favorite

IGF Signaling Pathway as a Selective Target of Familial Breast Cancer Therapy

By  

Current Molecular Medicine, Vol. 8, Iss. 8, 2008-12 ,pp. : 727-740

Bentham Science Publishers

Access to resources Recommend Favorite

Epigenetic regulation of tumor suppressors in t(8:21)-containing AML

By Yang Genyan  

Annals of Hematology, Vol. 83, Iss. 6, 2004-06 ,pp. : 329-330

Springer Publishing Company

Access to resources Recommend Favorite

CD44 Modulates Hs578T Human Breast Cancer Cell Adhesion, Migration, and Invasiveness

By Herrera-Gayol A.   Jothy S.  

Experimental and Molecular Pathology, Vol. 66, Iss. 1, 1999-04 ,pp. : 99-108

Elsevier

Access to resources Recommend Favorite